Identification of potential biomarkers of vaccine inflammation in mice

  1. Paul F McKay  Is a corresponding author
  2. Deniz Cizmeci
  3. Yoann Aldon
  4. Jeroen Maertzdorf
  5. January Weiner
  6. Stefan HE Kaufmann
  7. David JM Lewis
  8. Robert A van den Berg
  9. Giuseppe Del Giudice
  10. Robin J Shattock  Is a corresponding author
  1. Imperial College London, United Kingdom
  2. Max Planck Institute for Infection Biology, Germany
  3. Imperial College Healthcare NHS Trust, United Kingdom
  4. GlaxoSmithKline, United States
  5. GlaxoSmithKline, Italy

Abstract

Systems vaccinology approaches have been used to successfully define early signatures of the vaccine-induced immune response. However, the possibility that transcriptomics can also identify a correlate/surrogate for vaccine inflammation has not been fully explored. We have compared four licensed vaccines with known safety profiles, and three agonists of TLRs with known inflammatory potential, to elucidate the transcriptomic profile of an acceptable response to vaccination versus an inflammatory reaction. In mice, we looked at the transcriptomic changes in muscle at the injection site, the lymph node that drained the muscle and the PBMC isolated from the circulating blood from 4 hours and over the period of one week. A detailed examination and comparative analysis of these transcriptomes revealed a set of novel biomarkers reflective of inflammation after vaccination. These biomarkers are readily measurable in the peripheral blood, providing useful surrogates of inflammation, as a way to select candidates with acceptable safety profiles.

Data availability

Complete microarray data was deposited in NCBI's Gene Expression Omnibus and is accessible through GEO accession number GSE120661.

The following data sets were generated

Article and author information

Author details

  1. Paul F McKay

    Department of Medicine, Imperial College London, London, United Kingdom
    For correspondence
    p.mckay@imperial.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5195-6254
  2. Deniz Cizmeci

    Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3231-7726
  3. Yoann Aldon

    Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Jeroen Maertzdorf

    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Competing interests
    No competing interests declared.
  5. January Weiner

    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1438-7819
  6. Stefan HE Kaufmann

    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9866-8268
  7. David JM Lewis

    The NIHR Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom
    Competing interests
    No competing interests declared.
  8. Robert A van den Berg

    GlaxoSmithKline, Rockville, United States
    Competing interests
    Robert A van den Berg, is an employee of the GSK group of companies. Reports ownership of shares and/or restricted shares in GSK.
  9. Giuseppe Del Giudice

    GlaxoSmithKline, Siena, Italy
    Competing interests
    Giuseppe Del Giudice, is an employee of the GSK group of companies. Reports ownership of shares and/or restricted shares in GSK.
  10. Robin J Shattock

    Department of Medicine, Imperial College London, London, United Kingdom
    For correspondence
    r.shattock@imperial.ac.uk
    Competing interests
    No competing interests declared.

Funding

European Union Seventh Framework Programme (115308-2)

  • Paul F McKay
  • Deniz Cizmeci
  • Yoann Aldon
  • Jeroen Maertzdorf
  • January Weiner
  • Stefan HE Kaufmann
  • David JM Lewis
  • Robert A van den Berg
  • Guiseppe Del Giudice
  • Robin J Shattock

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Urszula Krzych, Walter Reed Army Institute of Research, United States

Ethics

Animal experimentation: The animal studies were approved by the Ethical Review Board of Imperial College London where the experiments were carried out and work was performed in strict compliance with project and personal animal experimentation licences granted by the UK government in accordance with the Animals in Scientific Procedures Act (1986)- PPL 70-7457 Protocol #1. Animals received minimal handling and their physical condition was monitored at least twice daily. All procedures were performed under isoflurane anaesthesia when appropriate, and all efforts were made to minimise suffering. There was a detailed protocol in place, as per requirement of the humane endpoints described in the animal licence, for early euthanasia in the event of onset of illness or significant deterioration in condition. At the end of the experiment all animals were culled using a schedule 1 method and death confirmed before necropsy. Food and water were supplied ad libitum.

Version history

  1. Received: February 16, 2019
  2. Accepted: May 13, 2019
  3. Accepted Manuscript published: May 14, 2019 (version 1)
  4. Version of Record published: June 7, 2019 (version 2)

Copyright

© 2019, McKay et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,250
    Page views
  • 429
    Downloads
  • 23
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paul F McKay
  2. Deniz Cizmeci
  3. Yoann Aldon
  4. Jeroen Maertzdorf
  5. January Weiner
  6. Stefan HE Kaufmann
  7. David JM Lewis
  8. Robert A van den Berg
  9. Giuseppe Del Giudice
  10. Robin J Shattock
(2019)
Identification of potential biomarkers of vaccine inflammation in mice
eLife 8:e46149.
https://doi.org/10.7554/eLife.46149

Share this article

https://doi.org/10.7554/eLife.46149

Further reading

    1. Developmental Biology
    2. Immunology and Inflammation
    Amir Hossein Kayvanjoo, Iva Splichalova ... Elvira Mass
    Research Article

    During embryogenesis, the fetal liver becomes the main hematopoietic organ, where stem and progenitor cells as well as immature and mature immune cells form an intricate cellular network. Hematopoietic stem cells (HSCs) reside in a specialized niche, which is essential for their proliferation and differentiation. However, the cellular and molecular determinants contributing to this fetal HSC niche remain largely unknown. Macrophages are the first differentiated hematopoietic cells found in the developing liver, where they are important for fetal erythropoiesis by promoting erythrocyte maturation and phagocytosing expelled nuclei. Yet, whether macrophages play a role in fetal hematopoiesis beyond serving as a niche for maturing erythroblasts remains elusive. Here, we investigate the heterogeneity of macrophage populations in the murine fetal liver to define their specific roles during hematopoiesis. Using a single-cell omics approach combined with spatial proteomics and genetic fate-mapping models, we found that fetal liver macrophages cluster into distinct yolk sac-derived subpopulations and that long-term HSCs are interacting preferentially with one of the macrophage subpopulations. Fetal livers lacking macrophages show a delay in erythropoiesis and have an increased number of granulocytes, which can be attributed to transcriptional reprogramming and altered differentiation potential of long-term HSCs. Together, our data provide a detailed map of fetal liver macrophage subpopulations and implicate macrophages as part of the fetal HSC niche.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Yuting Zhang, Min Zhang ... Guojiang Chen
    Research Article

    Marburg virus (MARV) is one of the filovirus species that cause deadly hemorrhagic fever in humans, with mortality rates up to 90%. Neutralizing antibodies represent ideal candidates to prevent or treat virus disease. However, no antibody has been approved for MARV treatment to date. In this study, we identified a novel human antibody named AF-03 that targeted MARV glycoprotein (GP). AF-03 possessed a high binding affinity to MARV GP and showed neutralizing and protective activities against the pseudotyped MARV in vitro and in vivo. Epitope identification, including molecular docking and experiment-based analysis of mutated species, revealed that AF-03 recognized the Niemann-Pick C1 (NPC1) binding domain within GP1. Interestingly, we found the neutralizing activity of AF-03 to pseudotyped Ebola viruses (EBOV, SUDV, and BDBV) harboring cleaved GP instead of full-length GP. Furthermore, NPC2-fused AF-03 exhibited neutralizing activity to several filovirus species and EBOV mutants via binding to CI-MPR. In conclusion, this work demonstrates that AF-03 represents a promising therapeutic cargo for filovirus-caused disease.